{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-22-000025","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.790254+00:00","generated_at":"2026-06-24T04:48:25.919743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth","bullets":["Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.","Voxzogo contributed $34.4M (first full quarter of U.S./EU sales); 446 children treated globally as of June 30.","FY2022 total revenue guidance raised to $2.06-2.16B; Voxzogo net product revenue guidance raised to $130-160M.","Expects EC approval of Roctavian for hemophilia A in Q3; BLA resubmission in U.S. planned for September 2022.","Kuvan revenues declined 27% YoY to $57.6M due to generic competition; total revenues growth excluding Kuvan was 13% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-22-000025","json":"https://secwatch.observer/filing/0001048477-22-000025.json","markdown":"https://secwatch.observer/filing/0001048477-22-000025.md","text":"https://secwatch.observer/filing/0001048477-22-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/0001048477-22-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/bmrn-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:48:25.919743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}